Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

Delayed Quote. Delayed  - 07/22 05:31:15 pm
82.35 CHF   +0.49%
07/22 NOVARTIS : IGI Securities Limited - Investor Kit
07/20DJBusiness Watch -- WSJ
07/19 NOVARTIS : Generic drug competition hits Novartis sales
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Novartis : IGI Securities Limited - Investor Kit

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/22/2016 | 04:04am CEST

Pharmaceuticals

Swiss pharmaceuticals firm Novartis AG said it has stopped making tuberculosis drugs in Pakistan in a dispute over pricing, prompting fears of a health crisis due to a shortage of drugs in a country with the world’s fifth-highest TB rates. http://tribune.com.pk/story/1145676/shortage-tb-drugs-swiss-pharmaceuticals-halt-production-pakistan/

(c) 2016 Pakistan Press International (PPI). All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS AG
07/22 NOVARTIS : IGI Securities Limited - Investor Kit
07/21 NOVARTIS : Patent Issued for Compounds Containing S-N-Valeryl-N-{-Methyl)-Valine..
07/21 NOVARTIS : IGI Securities Limited - Investor Kit
07/20DJBusiness Watch -- WSJ
07/19 NOVARTIS : Generic drug competition hits Novartis sales
07/19 NOVARTIS : beats 2Q profit forecasts
07/19DJNOVARTIS : Warns on Profit as It Boosts Investment in Heart-Failure Pill Entrest..
07/19DJNOVARTIS : Says Profit Could Dip
07/19 NOVARTIS : 2Q net slips as generic drug competition hits sales
07/19DJNOVARTIS : Warns Profit Could Fall This Year Due to Increased Spending on Entres..
More news
Sector news : Pharmaceuticals - NEC
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJBAYER : 2Q 2016 -- Forecast
07/22DJMonsanto Wins EU Nod for New Biotech Soybeans
07/21DJBIOGEN : Announces CEO Search, Lifts Guidance--2nd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/22 Biogen Needs To Fill Pipeline Or Rethink Strategy
07/21 Big Pharma Dominates Healthcare But Caregivers Are Top Sector Yield Dogs In J..
07/21 5 Key Messages From Novartis's Q2 Earnings Report You Shouldn't Miss
07/21 FDA Experts Back Brodalumab, With Warnings
07/21 NOVARTIS : On Road To Recovery?
Advertisement
Financials ($)
Sales 2016 48 867 M
EBIT 2016 11 412 M
Net income 2016 7 523 M
Debt 2016 14 038 M
Yield 2016 3,40%
P/E ratio 2016 24,24
P/E ratio 2017 22,00
EV / Sales 2016 4,78x
EV / Sales 2017 4,63x
Capitalization 219 526 M
More Financials
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 90,0 $
Spread / Average Target 7,8%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-5.13%219 526
JOHNSON & JOHNSON21.72%343 913
PFIZER INC.13.82%222 823
ROCHE HOLDING LTD.-9.62%218 832
MERCK & CO., INC.11.36%162 815
BRISTOL-MYERS SQUIBB C..10.02%126 333
More Results